SVRA Stock Overview
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Savara Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.23 |
| 52 Week High | US$5.70 |
| 52 Week Low | US$2.82 |
| Beta | 0.66 |
| 1 Month Change | -3.87% |
| 3 Month Change | -29.93% |
| 1 Year Change | -34.08% |
| 3 Year Change | 150.39% |
| 5 Year Change | 86.71% |
| Change since IPO | -63.13% |
Recent News & Updates
Recent updates
Savara: Rolling BLA Submission Of MOLBREEVI Generates Catalysts To Track
Dec 20Savara: Trial Successful, But I'm Only Half Convinced
Sep 09Savara: Today's Data 'Win' Rouses Market All Too Briefly
Jun 26Savara: The Binary Bet On Phase 3 Data
Jun 07Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Dec 14
Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Feb 16Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Oct 12Savara's rare lung disorder drug gets promising innovative medicine status in UK
Aug 26Savara GAAP EPS of -$0.06 in-line
Aug 11Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?
Jan 24Is Savara (NASDAQ:SVRA) A Risky Investment?
Jul 05Savara: They Failed Once, But They Are Trying Again
Jun 07The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares
Mar 17Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares
Feb 26Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Nov 24Savara EPS misses by $0.01
Nov 05Shareholder Returns
| SVRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.6% | -3.6% | -2.4% |
| 1Y | -34.1% | -2.6% | 23.4% |
Return vs Industry: SVRA underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: SVRA underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| SVRA volatility | |
|---|---|
| SVRA Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SVRA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SVRA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 37 | Matt Pauls | www.savarapharma.com |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
Savara Inc. Fundamentals Summary
| SVRA fundamental statistics | |
|---|---|
| Market cap | US$676.56m |
| Earnings (TTM) | -US$82.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.2x
P/E RatioIs SVRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SVRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$67.48m |
| Gross Profit | -US$67.48m |
| Other Expenses | US$15.46m |
| Earnings | -US$82.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 13.3% |
How did SVRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:47 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Savara Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dewey Steadman | Canaccord Genuity |
| Joshua Schimmer | Evercore ISI |
| Liisa Bayko | Evercore ISI |